Intragraft donor-specific anti-HLA antibodies in phenotypes of chronic lung allograft dysfunction.
Adult
Allografts
/ immunology
Antibodies
/ blood
Bronchiolitis Obliterans
/ immunology
Chronic Disease
Female
HLA Antigens
/ immunology
Humans
Lung Diseases
/ surgery
Lung Transplantation
Male
Middle Aged
Phenotype
Postoperative Complications
/ genetics
Retrospective Studies
Tissue Donors
Young Adult
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
29
04
2019
accepted:
31
07
2019
pubmed:
24
8
2019
medline:
18
11
2020
entrez:
24
8
2019
Statut:
epublish
Résumé
Circulating anti-human leukocyte antigen (HLA) serum donor-specific antibodies (sDSAs) increase the risk of chronic lung allograft dysfunction (CLAD) and mortality. Discrepancies between serological and pathological/clinical findings are common. Therefore, we aimed to assess the presence of tissue-bound graft DSAs (gDSAs) in CLAD explant tissue compared with sDSAs. Tissue cores, obtained from explant lungs of unused donors (n=10) and patients with bronchiolitis obliterans syndrome (BOS; n=18) and restrictive allograft syndrome (RAS; n=18), were scanned with micro-computed tomography before elution of antibodies. Total IgG levels were measured Overall, mean fluorescence intensity was higher in RAS eluates compared with BOS and controls (p<0.0001). In BOS, two patients were sDSA This study underlines the potential of gDSA assessment as complementary information to sDSA findings. The relevance and applications of gDSAs need further investigation.
Identifiants
pubmed: 31439680
pii: 13993003.00847-2019
doi: 10.1183/13993003.00847-2019
pii:
doi:
Substances chimiques
Antibodies
0
HLA Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright ©ERS 2019.
Déclaration de conflit d'intérêts
Conflict of interest: A. Sacreas has nothing to disclose. Conflict of interest: J-L. Taupin has nothing to disclose. Conflict of interest: M-P. Emonds has nothing to disclose. Conflict of interest: L. Daniëls has nothing to disclose. Conflict of interest: D.E. Van Raemdonck has nothing to disclose. Conflict of interest: R. Vos has nothing to disclose. Conflict of interest: G.M. Verleden has nothing to disclose. Conflict of interest: B.M. Vanaudenaerde has nothing to disclose. Conflict of interest: A. Roux reports personal fees and nonfinancial support from Biotest, personal fees from Thermo Fisher, nonfinancial support from CSL Berhing, outside the submitted work. Conflict of interest: S.E. Verleden has nothing to disclose.